BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 38359495)

  • 1. Predictive value of CDC37 gene expression for targeted therapy in metastatic colorectal cancer.
    Arai H; Yang Y; Baca Y; Millstein J; Denda T; Ou FS; Innocenti F; Takeda H; Kubota Y; Doi A; Horie Y; Umemoto K; Izawa N; Wang J; Battaglin F; Jayachandran P; Algaze S; Soni S; Zhang W; Goldberg RM; Hall MJ; Scott AJ; Hwang JJ; Lou E; Weinberg BA; Marshall J; Goel S; Xiu J; Michael Korn W; Venook AP; Sunakawa Y; Lenz HJ
    Eur J Cancer; 2024 Apr; 201():113914. PubMed ID: 38359495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical impact of primary tumour location, early tumour shrinkage, and depth of response in the treatment of metastatic colorectal cancer with first-line chemotherapy plus cetuximab or bevacizumab.
    Sagawa T; Sato Y; Hirakawa M; Hamaguchi K; Fukuya A; Okamoto K; Miyamoto H; Muguruma N; Fujikawa K; Takahashi Y; Takayama T
    Sci Rep; 2020 Nov; 10(1):19815. PubMed ID: 33188279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Primary Tumor Location on First-line Bevacizumab or Cetuximab in Metastatic Colorectal Cancer.
    Snyder M; Bottiglieri S; Almhanna K
    Rev Recent Clin Trials; 2018; 13(2):139-149. PubMed ID: 29595113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequential cetuximab/bevacizumab therapy is associated with improved outcomes in patients with wild-type KRAS exon 2 metastatic colorectal cancer.
    Hsu HC; Liu YC; Wang CW; Chou WC; Hsu YJ; Chiang JM; Lin YC; Yang TS
    Cancer Med; 2019 Jul; 8(7):3437-3446. PubMed ID: 31090176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary tumour side as a driver for treatment choice in RAS wild-type metastatic colorectal cancer patients: a systematic review and pooled analysis of randomised trials.
    Rossini D; Boccaccino A; Carullo M; Antoniotti C; Dima G; Ciracì P; Marmorino F; Moretto R; Masi G; Cremolini C
    Eur J Cancer; 2023 May; 184():106-116. PubMed ID: 36913832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial.
    Venook AP; Niedzwiecki D; Lenz HJ; Innocenti F; Fruth B; Meyerhardt JA; Schrag D; Greene C; O'Neil BH; Atkins JN; Berry S; Polite BN; O'Reilly EM; Goldberg RM; Hochster HS; Schilsky RL; Bertagnolli MM; El-Khoueiry AB; Watson P; Benson AB; Mulkerin DL; Mayer RJ; Blanke C
    JAMA; 2017 Jun; 317(23):2392-2401. PubMed ID: 28632865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Regorafenib in Combination with Chemotherapy as Second-Line Treatment in Patients with Metastatic Colorectal Cancer: A Network Meta-Analysis and Systematic Literature Review.
    Xie X; Zhang J; Hu H; Cai Y; Wu Z; Ling J; Li W; Deng Y
    Adv Ther; 2020 Oct; 37(10):4233-4248. PubMed ID: 32770529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment Patterns and Outcomes in Patients with KRAS Wild-Type Metastatic Colorectal Cancer Treated in First Line with Bevacizumab- or Cetuximab-Containing Regimens.
    Houts AC; Ogale S; Sommer N; Satram-Hoang S; Walker MS
    J Gastrointest Cancer; 2019 Mar; 50(1):69-77. PubMed ID: 29168112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single-Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial).
    García-Alfonso P; Benavides M; Falcó E; Muñoz A; Gómez A; Sastre J; Rivera F; Montagut C; Salgado M; López-Ladrón A; López R; Ruiz de Mena I; Durán G; Aranda E;
    Oncologist; 2018 Nov; 23(11):1271-e128. PubMed ID: 30120161
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cetuximab versus bevacizumab in metastatic colorectal cancer: a comparative effectiveness study.
    Marques RP; Godinho AR; Heudtlass P; Pais HL; Quintela A; Martins AP
    J Cancer Res Clin Oncol; 2020 May; 146(5):1321-1334. PubMed ID: 32144533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First-line therapy of bevacizumab plus chemotherapy versus cetuximab plus chemotherapy for metastatic colorectal cancer patients with mucinous adenocarcinoma or mucinous component.
    Zhou YW; Long YX; Chen Y; Liu JY; Pu D; Huang JY; Bi F; Li Q; Gou HF; Qiu M
    Cancer Med; 2021 May; 10(10):3388-3402. PubMed ID: 33939281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial.
    Stintzing S; Wirapati P; Lenz HJ; Neureiter D; Fischer von Weikersthal L; Decker T; Kiani A; Kaiser F; Al-Batran S; Heintges T; Lerchenmüller C; Kahl C; Seipelt G; Kullmann F; Moehler M; Scheithauer W; Held S; Modest DP; Jung A; Kirchner T; Aderka D; Tejpar S; Heinemann V
    Ann Oncol; 2019 Nov; 30(11):1796-1803. PubMed ID: 31868905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multicenter, randomized, double-blind phase 2 trial of FOLFIRI with regorafenib or placebo as second-line therapy for metastatic colorectal cancer.
    Sanoff HK; Goldberg RM; Ivanova A; O'Reilly S; Kasbari SS; Kim RD; McDermott R; Moore DT; Zamboni W; Grogan W; Cohn AL; Bekaii-Saab TS; Leonard G; Ryan T; Olowokure OO; Fernando NH; McCaffrey J; El-Rayes BF; Horgan AM; Sherrill GB; Yacoub GH; O'Neil BH
    Cancer; 2018 Aug; 124(15):3118-3126. PubMed ID: 29905927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Germ line polymorphisms of genes involved in pluripotency transcription factors predict efficacy of cetuximab in metastatic colorectal cancer.
    Arai H; Millstein J; Loupakis F; Stintzing S; Wang J; Battaglin F; Kawanishi N; Jayachandran P; Soni S; Zhang W; Mumenthaler SM; Cremolini C; Heinemann V; Falcone A; Lenz HJ
    Eur J Cancer; 2021 Jun; 150():133-142. PubMed ID: 33901792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FOLFOXIRI Plus Cetuximab or Bevacizumab as First-Line Treatment of
    Stintzing S; Heinrich K; Tougeron D; Modest DP; Schwaner I; Eucker J; Pihusch R; Stauch M; Kaiser F; Kahl C; Karthaus M; Müller C; Burkart C; Reinacher-Schick A; Kasper-Virchow S; Fischer von Weikersthal L; Krammer-Steiner B; Prager GW; Taieb J; Heinemann V
    J Clin Oncol; 2023 Sep; 41(25):4143-4153. PubMed ID: 37352476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutational profiles of metastatic colorectal cancer treated with FOLFIRI plus cetuximab or bevacizumab before and after secondary resection (AIO KRK 0306; FIRE-3).
    Stahler A; Heinemann V; Holch JW; von Einem JC; Westphalen CB; Heinrich K; Schlieker L; Jelas I; Alig AHS; Fischer LE; Weiss L; Modest DP; von Weikersthal LF; Decker T; Kiani A; Moehler M; Kaiser F; Kirchner T; Jung A; Stintzing S
    Int J Cancer; 2021 Dec; 149(11):1935-1943. PubMed ID: 34310714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of
    Tsai HL; Chen YC; Yin TC; Su WC; Chen PJ; Chang TK; Li CC; Huang CW; Wang JY
    Oncol Res; 2022 May; 29(1):47-61. PubMed ID: 35177165
    [No Abstract]   [Full Text] [Related]  

  • 18. Long-term Survival Update and Extended RAS Mutational Analysis of the CAIRO2 Trial: Addition of Cetuximab to CAPOX/Bevacizumab in Metastatic Colorectal Cancer.
    Ten Hoorn S; Mol L; Sommeijer DW; Nijman L; van den Bosch T; de Back TR; Ylstra B; van Dijk E; van Noesel CJM; Reinten RJ; Nagtegaal ID; Koopman M; Punt CJA; Vermeulen L
    Clin Colorectal Cancer; 2023 Mar; 22(1):67-75. PubMed ID: 36564280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regorafenib in Patients with Antiangiogenic-Naïve and Chemotherapy-Refractory Advanced Colorectal Cancer: Results from a Phase IIb Trial.
    Riechelmann RP; Leite LS; Bariani GM; Glasberg J; Rivelli TG; da Fonseca LG; Nebuloni DR; Braghiroli MI; Queiroz MA; Isejima AM; Kappeler C; Kikuchi L; Hoff PM
    Oncologist; 2019 Sep; 24(9):1180-1187. PubMed ID: 31175167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma Protein Biomarkers in Advanced or Metastatic Colorectal Cancer Patients Receiving Chemotherapy With Bevacizumab or Cetuximab: Results from CALGB 80405 (Alliance).
    Nixon AB; Sibley AB; Liu Y; Hatch AJ; Jiang C; Mulkey F; Starr MD; Brady JC; Niedzwiecki D; Venook AP; Baez-Diaz L; Lenz HJ; O'Neil BH; Innocenti F; Meyerhardt JA; O'Reilly EM; Owzar K; Hurwitz HI
    Clin Cancer Res; 2022 Jul; 28(13):2779-2788. PubMed ID: 34965954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.